Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6874233 | 0.86 | CTSL (0.46) | SMN1; SMN2LMNACTSLCTSSCTSK | |
| SCHEMBL5528437 | 0.84 | CTSL (0.48) | SMN1; SMN2LMNACTSLCTSSCTSV | |
| SCHEMBL6590412 | 0.84 | SMYD3 (0.46) | SMN1; SMN2LMNACTSLCTSSCTSK | |
| SCHEMBL5529202 | 0.83 | CTSL (0.61) | PYGLCYP2C9CTSLCTSSCTSV | |
| SCHEMBL5522783 | 0.81 | CTSL (0.53) | CTSLCTSSCTSVCTSKCTSB | |
| SCHEMBL7562354 | 0.80 | CTSL (0.48) | SMN1; SMN2CTSLCTSSCTSVCTSK | |
| SCHEMBL5526266 | 0.80 | CTSL (0.53) | LMNACTSLCTSSCTSVCTSK | |
| SCHEMBL5528527 | 0.80 | CTSL (0.48) | LMNACTSLCTSSCTSVCTSK | |
| SCHEMBL5525358 | 0.79 | PRMT5 (0.51) | SMN1; SMN2CTSLCTSSCTSKCTSB | |
| SCHEMBL5534377 | 0.79 | CTSL (0.49) | SMN1; SMN2CTSLCTSSCTSVCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | PYGL 1525/4885CYP2C9 1293/4885SMN1; SMN2 3462/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | PYGL 1525/4885CYP2C9 1293/4885SMN1; SMN2 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.